Following the March 2025 placing, TheraCryf identified two final milestones to achieve clinical readiness for its Ox-1 programme: manufacturing scale-up and completion of 28-day regulatory toxicology studies. The company has now delivered the first of these, successfully scaling Ox-1 drug substance production to 10kg on schedule and at a yield exceeding expectations. Manufacturing scale-up is a significant milestone because it’s the point where a drug stops being “something one can make in the lab” and becomes “something one can reliably supply” for regulated studies and, eventually, patients. Theracryf are on track to deliver them during 2026. Positive.
